🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Alshad S. Lalani

Puma Biotechnology (United States)

ORCID: 0000-0003-4891-9983
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

(2023)10.1158/1078-0432.c.6531065.v1
Top 100%
0DataRank
Top 100%0 citations

Sheau‐Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bédard +18 more

Papers

Driven by 7 papers — median percentile 0. Top paper: “Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer”.

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-1844
N/A
0.564DataRank · unranked
42 citations

Mari Kuraguchi, Man Xu, Andrew Portell, Luke J. Taus, Irmina Diala +17 more

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

Cancer Cell(2021)10.1016/j.ccell.2021.06.001
N/A
0DataRank · unranked
103 citations

Benjamin P. Brown, Jens Meiler, Arnaldo Marín, Harikrishna Sekar Jayanthan, Dan Ye +13 more

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0215
N/A
0DataRank · unranked
293 citations

Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai +44 more

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

npj Breast Cancer(2021)10.1038/s41523-021-00274-0
N/A
0DataRank · unranked
11 citations

Carolina Gutiérrez, Vidyalakshmi Sethunath, Sepideh Mehravaran, Mario Giuliano, Martin J. Shea +16 more

Natural History and Characteristics of ERBB2 -mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-0885
N/A
0DataRank · unranked
3 citations

Sheau‐Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bédard +18 more

Data from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

(2023)10.1158/1078-0432.c.6531065.v1
Top 100%
0DataRank
Top 100%0 citations

Sheau‐Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bédard +18 more

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Biomedicines(2021)10.3390/biomedicines9070740
N/A
0DataRank · unranked
19 citations

Huey Liu, Troy Pearson, Toshiaki Iwase, Jon A. Fuson, Alshad S. Lalani +6 more